Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05940324 · ClinicalTrials.gov registry record · Phase 2
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
A Phase 2 study of Obsessive - Compulsive Disorder, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05940324: Recruiting Phase 2 study of Obsessive - Compulsive Disorder, sponsored by Stanford University.
NCT05940324 is a Phase 2 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 150 participants, below the 2,063-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05940324, a Phase 2 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
Primary Outcome
Change in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Naltrexone Pill
- OTHER Placebo pill
Study Locations (1)
California
- Department of Psychiatry & Behavioral Sciences - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-02-24 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
What NCT05940324 shows while recruiting
NCT05940324 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,063-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 3 interventions - of which Ketamine is the first listed.
NCT05940324 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05940324 about?
NCT05940324 is a clinical study titled "Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)". The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
What is the current status of trial NCT05940324?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-02-24. Estimated completion is 2028-11.
What conditions does trial NCT05940324 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT05940324?
The interventions under investigation include: Ketamine (DRUG), Naltrexone Pill (DRUG), Placebo pill (OTHER).
Who is sponsoring clinical trial NCT05940324?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05940324 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05940324's enrollment target sits among peer trials
150 21st of 84 higher than 64 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
RECRUITING · Phase 2
-
Efficacy of Nitrous Oxide in OCD: Pilot Study
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Study of Dextromethorphan in OCD and Related Disorders
RECRUITING · Phase 2
-
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Understanding How Ketamine Brings About Rapid Improvement in OCD
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI